Date of download: 7/9/2016 From: Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review Ann.

Slides:



Advertisements
Similar presentations
Platelet Aggregation Inhibitors
Advertisements

Hemostasis & Thrombosis: Platelet Disorders Beth A. Bouchard BIOC 212: Biochemistry of Human Disease Spring 2005.
Thrombus Susceptibility and the Vulnerable Plaque Relationship Between Inflammation and Thrombosis.
Anti-platelet drugs Dr. Ishfaq Bukhari Dec
Antiplatelet Drugs (Anti-thrombotics)
Dr. Ishfaq Bukhari.  In healthy vasculature, circulating platelets are maintained in an inactive state by nitric oxide (NO) and prostacyclinre (PGI2)leased.
Ticlopidine (Ticlid™) and Clopidogrel (Plavix™) Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.
Hemostasis Constriction of vessel Aggregation of platelets
ANTIPLATELET DRUGS.
ANTIPLATELET DRUGS Learning objectives By the end of this lecture, students should be able to: - describe different classes of anti-platelet drugs and.
ANTIPLATELETES AGENTS BY :DR. ISRAA OMAR. The role of platelets Platelets play a critical role in thromboembolic disease like ischemic heart disease and.
ANTIPLATELETES AGENTS
Antiplatelet drugs Prof. Hanan Hagar Learning objectives By the end of this lecture, students should be able to to describe different classes of anti-platelet.
Antiplatelet drugs Prof. Hanan Hagar Learning objectives By the end of this lecture, students should be able to To describe the role of platelets in.
Prof. Abdulrahman Almotrefi
Date of download: 5/30/2016 Copyright © The American College of Cardiology. All rights reserved. From: Differential Inhibition of Human Atherosclerotic.
Date of download: 5/31/2016 From: Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis Ann Intern Med. 2015;163(12):
J Am Coll Cardiol. 2015;65(24): doi: /j.jacc Figure Legend:
Date of download: 6/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Fatty Acids and Cardiovascular Disease: Effects.
Date of download: 6/3/2016 From: Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial.
Date of download: 6/3/2016 From: Elevated Plasma Homocysteine Level Is an Independent Predictor of Coronary Heart Disease Events in Patients with Type.
Date of download: 6/3/2016 From: The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease:
Date of download: 6/3/2016 From: Radial Versus Femoral Access in Invasively Managed Patients With Acute Coronary Syndrome: A Systematic Review and Meta-analysis.
Date of download: 6/6/2016 From: Comparative Effectiveness of Pain Management Interventions for Hip Fracture: A Systematic Review Ann Intern Med. 2011;155(4):
Date of download: 6/17/2016 From: Treatment of Rheumatoid Arthritis with Gammalinolenic Acid Ann Intern Med. 1993;119(9): doi: /
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Multifaceted Clinical Readouts of Platelet Inhibition.
Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: Discovery of a New Role of Human Resistin in Hepatocyte.
Date of download: 6/25/2016 From: Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis Ann Intern Med. 2015;163(3):
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Amyloid-Beta (1-40) and the Risk of Death From Cardiovascular.
Date of download: 7/1/2016 Copyright © 2016 McGraw-Hill Education. All rights reserved. Evaluation of patients for inherited abnormalities in platelet.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Platelet Biology and Response to Antiplatelet Therapy.
Date of download: 9/17/2016 From: Topical Treatment of Pressure Ulcers with Nerve Growth Factor: A Randomized Clinical Trial Ann Intern Med. 2003;139(8):
Date of download: 9/18/2016 From: The Cardiomyopathy of Overload: An Unnatural Growth Response in the Hypertrophied Heart Ann Intern Med. 1994;121(5):
Date of download: 9/19/2016 From: The Implications of Regional Variations in Medicare Spending. Part 2: Health Outcomes and Satisfaction with Care Ann.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Aspirin and Cancer J Am Coll Cardiol. 2016;68(9):
II. Antiplatelet Drugs.
From: Two Ways of Knowing: Big Data and Evidence-Based Medicine
A. Mechanism of action of aspirin
From: Effects of Low-Carbohydrate and Low-Fat DietsA Randomized Trial
Ann Intern Med. 2014;160(11): doi: /M Figure Legend:
Antithrombotic drugs Fibrinolytics
Anesthes. 1997;87(3): Figure Legend:
Ann Intern Med. 2014;160(9): doi: /M Figure Legend:
From: Narrative Review: The Emerging Clinical Implications of the Role of Aldosterone in the Metabolic Syndrome and Resistant Hypertension Ann Intern Med.
Aspirin and Clopidogrel Resistance
From: Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 American College of Cardiology/American.
Evaluation of patients for inherited abnormalities in platelet number or function. The major and well-recognized entities are shown here. A reduced platelet.
Effect of Low Cholesterol on Steroid Hormones and Vitamin E Levels
Platelets in Atherothrombosis
Figure 1 Newly discovered mechanistic pathways
Figure 1 Mechanism of thrombus formation during ST-segment
Volume 55, Issue 6, Pages (December 2011)
Aspirin and Clopidogrel Resistance
Ding Ai, John Y.-J. Shyy, Yi Zhu  Kidney International 
Perioperative management of antiplatelet therapy
Paul A. Gurbel, and Udaya S. Tantry JCHF 2014;2:1-14
Jonathan C. Cohen, PhD  Journal of Clinical Lipidology 
Antithrombotic and prothrombotic molecules Content Points:
Volume 141, Issue 2, Pages e89S-e119S (February 2012)
Figure 1 Statins, ezetimibe, and PCSK9 inhibitors all increase the expression of LDL receptors and reduce LDL-cholesterol levels (by percentages shown)
Figure 1 Mechanisms of platelet adhesion and aggregation
Volume 81, Issue 12, Pages (June 2012)
Prof. Abdulrahman Almotrefi
Antiplatelet Drugs Dr. : Asmaa Fady MD., MSC, M.B, B.Ch
Figure 2 Protective functions of HDL
Section B: Science update
Volume 141, Issue 2, Pages e89S-e119S (February 2012)
Ticagrelor: agonising over its mechanisms of action
Platelet activation pathways and sites targeted by current and novel antiplatelet agents. Platelet activation pathways and sites targeted by current and.
Presentation transcript:

Date of download: 7/9/2016 From: Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review Ann Intern Med. 2016;164(9): doi: /M Several adverse mechanisms on coronary plaque by PCSK9. ACS = acute coronary syndrome; LDL = low-density lipoprotein; MMP = matrix metalloproteinase; NF-κB = nuclear factor-κB; PCSK9 = proprotein convertase subtilisin/kexin type 9. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Date of download: 7/9/2016 From: Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review Ann Intern Med. 2016;164(9): doi: /M Time pattern of change of PCSK9 levels from experimental studies. AMI = acute myocardial infarction; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; PCSK9 = proprotein convertase subtilisin/kexin type 9. * Evidence from animal studies. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Date of download: 7/9/2016 From: Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review Ann Intern Med. 2016;164(9): doi: /M Potential antiplatelet effects of PCSK9 antibodies. Native LDL binds to the ApoER2 and activates cPLA 2 through the p38 MAPK pathway. cPLA 2 releases AA from membrane phospholipids that is converted to prostaglandin H 2 by the COX-1 enzyme and subsequently to TxA 2 by Tx synthase. TxA 2 acts synergistically with downstream signaling generated by the binding of platelet agonists (ADP, collagen, and thrombin) to respective receptors to activate GPIIb/IIIa receptors. Activated GPIIb/IIIa receptors from adjacent platelets bind to fibrinogen, which causes platelet aggregation and thrombosis at the site of plaque rupture. Similarly, oxLDL binds to scavenger receptors (CD36 and SRA) and activates p38 MAPK. PCSK9 antibodies prevent LDL receptor degradation and thereby enhance LDL cholesterol clearance from the circulation. The latter effect decreases the platelet activation and aggregation induced by native LDL and oxLDL. AA = arachidonic acid; ACS = acute coronary syndrome; ADP = adenosine diphosphate; ApoER2 = apolipoprotein E receptor-2; COX-1 = cyclooxygenase-1; cPLA 2 = cytosolic phospholipase A 2 ; GPIIb/IIIa = glycoprotein IIb/IIIa; LDL = low-density lipoprotein; mLPA = membrane phospholipids; oxLDL = oxidized low-density lipoprotein; p38 MAPK = p38 mitogen-activated protein kinase ; PCSK9 = proprotein convertase subtilisin/kexin type 9; SRA = scavenger receptor A; Tx = thromboxane; TxA 2 = thromboxane A 2. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.